Has anyone heard of biotech analyst Mark Schoenebaum?
Unfortunately, he passed in 2019. This article speaks so highly of him. Is this type of analyst common in ER?
https://news.yahoo.com/mark-schoenebaum-best-biotech-analyst-175140199.html
Mark Schoenebaum was a brilliant and successful Wall Street research analyst who fundamentally changed the way sell-siders cover biotech stocks. More importantly, Mark was a remarkably nice guy. Wall Street is not known for warm and fuzzy people, but Mark smashed that mold. He was kind and funny. He was gregarious and uncommonly generous to colleagues, friends, and even strangers.
Most of the biotech investment community first heard about Mark's death via a gut-wrenching email sent by his friend and former colleague Umer Raffat on Sunday evening.
“我们都仰望他是最好的equity research analyst there hasever been on Wall Street," Raffat wrote. "But that was only part of who he was: he was an absolute standout individual who touched so many lives, and whose strength of character showed in his sheer humility despite his absolutely unprecedented success."
As news of Mark's untimely death spread on Twitter, others took time to post their own fond remembrances. In all of these tweets, there was a common thread: Mark's humanity, thoughtfulness, and generosity. He made time for people. He was a mentor. He offered指导帮助,建议.
Thistweet，从@sanderduncan那里得到了很好的纪念马克：“我24岁，完全没用，但他毫不犹豫地提供帮助。”
这也是我知道的标记。作为涵盖生物技术与华尔街交集的记者，马克是信息，上下文和分析的宝贵来源。他知道一切 - 似乎是每个人 - 在生物技术中正在发生。而其他sell-sideanalysts walled themselves off for the sake of paying institutional investor clients, Mark made himself astonishingly accessible. He freely shared his research reports with journalists. You were invited to listen to his conference calls and log into his webinars. He was quick to return texts and emails. And if travel or his insanely busy schedule got in the way, he would apologize for taking so long to respond.
I'm heading into my 20th year covering biotech, which makes me 1) very old, but 2) uniquely qualified to place Mark's Wall Street career in its proper perspective. So, I say this without a hint of hyperbole: Mark was the most influential sell-side analyst that I've ever known.
有很多聪明people in this business, but Mark's genius was understanding the changing role of sell-side health care research on Wall Street. Investors wanted an honest information broker, not a stock picker. Mark understood that investors didn't care about his buy or sell recommendations, or his price targets. What they needed, even craved, was fast access to clinical data, analysis, and historical perspective.
Mark was the best at his job because he was the guy on Wall Street whom health care specialists and generalist investors turned to most for understanding the why of biotech investing. He made the complex easy to understand. He sent emails - lots and lots of emails. Really, so many emails. He used big fonts and rainbow colors. He was like a slightly nerdy but exuberant biotech teacher. He loved biotech and it was that passion that made us all love attending his class.
Mark exited Wall Street and biotech research in the middle of 2017. By the time he left, other analysts were emulating his style and methods. It's a testament to Mark's mentoring abilities that Umer Raffat, his former associate and pupil, has succeeded to become the industry's top biotech and pharma analyst.
Last December, I sent Mark a "let's catch up" email after he had posted on LinkedIn about considering a return to biotech. In typical Mark fashion, he responded to my email as if I was doing him a great honor by bugging him with questions.
“嘿，亚当！很高兴收到你的来信，我的朋友。你好吗？JPMorganconference. Sound like a deal? I can't thank you enough for the email. Very thoughtful of you. Sorry I have not done a better job of staying in touch with you over the last few years."
We finally had a chance to speak with each other in February. We spent about an hour on the phone, catching up. He was excited about the possibility of getting back into the biotech world in some fashion, perhaps running a startup or joining a company asCFO. He sounded relaxed, well rested, at peace.
他听起来像是旧的标记 - 我们都非常想念的那个家伙。
Comments (1)
Aut sit et ut vel et tempore. Rerum quis quam dolorem perferendis atque doloribus aut neque. Deserunt quam sunt ipsum velit. Modi at delectus fugiat.
EST LAUDANTIUM EST SAEPE ATQUE SUNT。Reactuntur Dolores依赖者Quis Est evehenderit Sint Provents。ConsectEtur Sunt Est et repellendus Expedita placeeat Recatur Rerum。ipsum quos maiores doloribus liberam molestias quis官员。
查看所有评论 - 100％免费
WSO取决于每个人都知道某事时能够参与进来。解锁您的电子邮件并获得奖金：6 financial modeling lessons free($199 value)
orUnlockwith your social account...